{"filing":{"accession_number":"0001104659-26-074025","cik":"0001408443","ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"tm2617859d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/tm2617859d1_8k.htm"},"events":[{"id":11013,"run_id":9652,"accession_number":"0001104659-26-074025","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Milestone Pharmaceuticals held its Annual Meeting and disclosed voting results on four proposals: election of eight directors, ratification of PricewaterhouseCoopers LLP as auditor, approval of an amendment to the 2019 Equity Incentive Plan increasing authorized shares by 6.8 million, and an advisory vote on executive compensation.","company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7486,"accession_number":"0001104659-26-074025","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on shareholder approval of an amendment to the 2019 Equity Incentive Plan increasing authorized shares by 6,800,000 for equity grants. This is a compensatory arrangement amendment affecting the pool of shares available for director and officer equity compensation, which is the hallmark of exec_compensation disclosures under Item 5.02(e). The material increase in authorized shares is significant to investors assessing dilution and executive incentive structures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:08:43.460254+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7487,"accession_number":"0001104659-26-074025","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final tally of votes cast at Milestone Pharmaceuticals' Annual Meeting on four proposals: election of eight directors, ratification of PricewaterhouseCoopers LLP as auditor, approval of the 2019 Equity Incentive Plan amendment (increasing authorized shares by 6.8 million), and an advisory vote on executive compensation. The detailed vote counts for each proposal are the core content of the filing, making this a textbook shareholder_vote_results event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:08:43.460254+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7486,"accession_number":"0001104659-26-074025","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on shareholder approval of an amendment to the 2019 Equity Incentive Plan increasing authorized shares by 6,800,000 for equity grants. This is a compensatory arrangement amendment affecting the pool of shares available for director and officer equity compensation, which is the hallmark of exec_compensation disclosures under Item 5.02(e). The material increase in authorized shares is significant to investors assessing dilution and executive incentive structures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:08:43.460254+00:00","company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","filing_date":"2026-06-15"},{"id":7487,"accession_number":"0001104659-26-074025","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final tally of votes cast at Milestone Pharmaceuticals' Annual Meeting on four proposals: election of eight directors, ratification of PricewaterhouseCoopers LLP as auditor, approval of the 2019 Equity Incentive Plan amendment (increasing authorized shares by 6.8 million), and an advisory vote on executive compensation. The detailed vote counts for each proposal are the core content of the filing, making this a textbook shareholder_vote_results event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:08:43.460254+00:00","company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","filing_date":"2026-06-15"}]}